TR201807912T4 - Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. - Google Patents
Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇.Info
- Publication number
- TR201807912T4 TR201807912T4 TR2018/07912T TR201807912T TR201807912T4 TR 201807912 T4 TR201807912 T4 TR 201807912T4 TR 2018/07912 T TR2018/07912 T TR 2018/07912T TR 201807912 T TR201807912 T TR 201807912T TR 201807912 T4 TR201807912 T4 TR 201807912T4
- Authority
- TR
- Turkey
- Prior art keywords
- synthesis methods
- phosphate receptor
- chiral synthesis
- receptor regulators
- regulators
- Prior art date
Links
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 108091006073 receptor regulators Proteins 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Agronomy & Crop Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26130109P | 2009-11-13 | 2009-11-13 | |
| US26247409P | 2009-11-18 | 2009-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807912T4 true TR201807912T4 (tr) | 2018-06-21 |
Family
ID=43992106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07912T TR201807912T4 (tr) | 2009-11-13 | 2010-11-15 | Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. |
Country Status (32)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780433C (en) * | 2009-11-13 | 2018-01-02 | Receptos, Inc. | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| RS61829B1 (sr) | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| RS56073B1 (sr) * | 2012-06-21 | 2017-10-31 | Eisai R&D Man Co Ltd | Novi derivati indansulfamida |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| US20170165236A1 (en) * | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| WO2016164180A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| EP4566676A3 (en) | 2016-06-14 | 2025-11-05 | Receptos LLC | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| ES2877686T3 (es) | 2016-07-22 | 2021-11-17 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Agonista S1P1 y aplicación del mismo |
| CN109563059A (zh) | 2016-08-19 | 2019-04-02 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| US11117875B2 (en) | 2016-09-14 | 2021-09-14 | Hangzhou Solipharma Co., Ltd. | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod |
| US10882830B2 (en) | 2016-09-14 | 2021-01-05 | Receptos Llc | Crystal form of ozanimod hydrochloride and processes for preparation therefor |
| WO2018064356A1 (en) | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
| EP3590929B1 (en) * | 2017-02-28 | 2021-09-15 | Medshine Discovery Inc. | Spiro compound and use thereof |
| CN110612292A (zh) * | 2017-04-07 | 2019-12-24 | 杭州领业医药科技有限公司 | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| US11207301B2 (en) | 2017-05-08 | 2021-12-28 | Receptos Llc | Sphingosine 1 phosphate receptor agonists for neuroprotection |
| WO2018215807A1 (en) * | 2017-05-22 | 2018-11-29 | Egis Gyógyszergyár Zrt. | Process for the production of ozanimod |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| US11117876B2 (en) | 2017-08-31 | 2021-09-14 | Receptos Llc | Crystalline form of ozanimod hydrochloride, and processes for preparation thereof |
| WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| CN107857760A (zh) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | 鞘氨醇‑1‑磷酸受体调节剂及其应用 |
| JP2021511375A (ja) | 2018-01-18 | 2021-05-06 | シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド | 三環式化合物の結晶形、塩形及びその製造方法 |
| WO2019181854A1 (ja) | 2018-03-20 | 2019-09-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | てんかん治療剤 |
| CN110615747A (zh) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | 一种二氢茚中间体的制备方法 |
| CA3124986A1 (en) | 2018-06-25 | 2020-01-02 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| AU2019338657A1 (en) | 2018-09-12 | 2021-03-18 | Pharmazell Gmbh | A process for the preparation of Ozanimod and its intermediate (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| WO2020115200A1 (en) * | 2018-12-07 | 2020-06-11 | Synthon B.V. | Improved process for preparing ozanimod |
| JP2022528467A (ja) * | 2019-03-29 | 2022-06-10 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１リン酸受容体調節因子 |
| KR20210151068A (ko) * | 2019-03-29 | 2021-12-13 | 리셉토스 엘엘씨 | 스핑고신 1 포스페이트 수용체 조절제 |
| JP2022527999A (ja) * | 2019-03-29 | 2022-06-07 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１リン酸受容体調節因子 |
| EP3959204A4 (en) * | 2019-04-26 | 2022-12-28 | Receptos Llc | SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| MX2022000651A (es) | 2019-07-16 | 2022-03-11 | Synthon Bv | Proceso mejorado para preparar ozanimod. |
| KR20220093330A (ko) | 2019-10-31 | 2022-07-05 | 이도르시아 파마슈티컬스 리미티드 | Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합 |
| BR112022012846A2 (pt) * | 2020-01-06 | 2022-09-06 | Arena Pharm Inc | Métodos de tratamento de condições relacionadas ao receptor s1p1 |
| US11760751B2 (en) | 2020-03-04 | 2023-09-19 | Helioeast Science & Technology Co., Ltd. | Benzo 2-azaspiro[4.4]nonane compound and use thereof |
| JP7443550B2 (ja) * | 2020-03-04 | 2024-03-05 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | 三環系化合物及びその使用 |
| WO2021188326A1 (en) * | 2020-03-17 | 2021-09-23 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
| KR20220160009A (ko) | 2020-03-27 | 2022-12-05 | 리셉토스 엘엘씨 | 스핑고신 1 포스페이트 수용체 조절제 |
| EP4126828A1 (en) * | 2020-03-27 | 2023-02-08 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| EP4126826A1 (en) | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| CN111620788B (zh) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| CN116867771B (zh) * | 2021-04-09 | 2025-08-26 | 南昌弘益药业有限公司 | 噁二唑取代的螺环类化合物及其应用 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| CN119462405B (zh) * | 2025-01-10 | 2025-05-27 | 天津阿尔塔科技有限公司 | 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) * | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| EP0583346A1 (en) | 1991-04-12 | 1994-02-23 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| ID25477A (id) * | 1998-01-23 | 2000-10-05 | Sankyo Co | Turunan-turunan spiropiperidin |
| AR035585A1 (es) † | 2000-09-15 | 2004-06-16 | Pharmacia Corp | Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
| DK1618098T3 (en) | 2003-04-11 | 2015-01-12 | Ptc Therapeutics Inc | 1,2,4-OXADIAZOLBENZOESYREFORBINDELSER AND THEIR USE FOR nonsense CONTROL AND TREATMENT OF AN ILLNESS |
| JP2007528872A (ja) * | 2003-10-01 | 2007-10-18 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物 |
| CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| JP2008531546A (ja) | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| JP5665271B2 (ja) † | 2005-08-03 | 2015-02-04 | ノバルティス アーゲー | 骨髄腫の処置のためのｈｄａｃ阻害剤の使用 |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| PE20070705A1 (es) * | 2005-11-25 | 2007-08-23 | Basf Ag | Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales |
| US7902336B2 (en) | 2005-12-21 | 2011-03-08 | Joseph Gabriele | Catecholamine regulated protein |
| WO2007105053A2 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2008035239A1 (en) * | 2006-09-21 | 2008-03-27 | Actelion Pharmaceuticals Ltd | Phenyl derivatives and their use as immunomodulators |
| AU2007323540A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| SG177221A1 (en) | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008106226A2 (en) | 2007-02-28 | 2008-09-04 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| ES2549761T3 (es) | 2008-05-14 | 2015-11-02 | The Scripps Research Institute | Nuevos moduladores de los receptores de esfingosina fosfato |
| CN102066752B (zh) * | 2008-06-13 | 2014-02-19 | (学)斗源学院 | 具有回转阀的往复式压缩机 |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| RS61829B1 (sr) | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| EP2498609B1 (en) | 2009-11-13 | 2018-04-18 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CA2780433C (en) | 2009-11-13 | 2018-01-02 | Receptos, Inc. | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EP2706999B1 (en) | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
-
2010
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
- 2010-11-15 SI SI201031704T patent/SI2498610T2/sl unknown
- 2010-11-15 SM SM20180288T patent/SMT201800288T1/it unknown
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active Active
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 PL PL10830880.0T patent/PL2498610T5/pl unknown
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 EP EP10830880.0A patent/EP2498610B2/en active Active
- 2010-11-15 PH PH1/2012/500939A patent/PH12012500939A1/en unknown
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en not_active Ceased
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 SM SM20210169T patent/SMT202100169T1/it unknown
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 DK DK10830880.0T patent/DK2498610T4/da active
- 2010-11-15 HR HRP20180874TT patent/HRP20180874T4/hr unknown
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active Active
- 2010-11-15 RS RS20180647A patent/RS57253B2/sr unknown
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 ES ES10830880T patent/ES2673160T5/es active Active
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-18 LU LU00184C patent/LUC00184I2/en unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I2/el unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
-
2024
- 2024-02-29 FI FIEP10830880.0T patent/FI2498610T4/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201807912T4 (tr) | Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. | |
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
| EA201200507A1 (ru) | Применение активаторов никотинового ацетилхолинового рецептора альфа 7 | |
| ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
| BR112012022513A2 (pt) | derivados de piperidin-4-il azetidina como inibidores de jak1 | |
| TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
| BR112014027165A2 (pt) | antagonistas de st2l e métodos de uso | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| DE602007012072D1 (de) | Orantagonisten | |
| EP2529355A4 (en) | VOICE BODY IDENTITY CORRELATION | |
| EP2498609A4 (en) | SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | |
| MX2013012652A (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12. | |
| UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
| EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
| IL206359A0 (en) | Sulfonamides as orexin antagonists | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| BRPI1013777A8 (pt) | Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| MX379538B (es) | Moduladores novedosos de receptores de fosfato de esfingosina. | |
| BR112014007451A2 (pt) | síntese in vivo de fibras elásticas | |
| CR20120502A (es) | Uso de nuevos inhibidores de pan-cdk para tratar tumores | |
| BR112015008389A2 (pt) | compostos úteis na síntese de compostos de benzamida |